DiscoveryBioMed Garners Funding from the National Institutes of Health (NIH) to Support a Metabolic Diseases Drug Discovery Program

BIRMINGHAM, Ala.--(BUSINESS WIRE)--DiscoveryBioMed, Inc. (DBM) announces today funding of its Phase I Small Business Innovation Research (SBIR) grant, totaling nearly $222,000, by the National Center for Complementary and Alternative Medicine (NCCAM) at the National Institute of Health. The award will focus on high-throughput screening and discovery of new drugs that stimulate endogenous secretion of adiponectin, an established biomarker with multiple salutary effects on the prevention of obesity-related diseases, from human adipocytes.